Eli Lil­ly hits pause on Aduhelm ri­val do­nanemab as ex­ecs fret about Medicare's skep­ti­cal stance on Alzheimer's drug class

While Bio­gen is still fight­ing to save its con­tro­ver­sial drug Aduhelm from drown­ing in crit­i­cism, Eli Lil­ly ex­ecs echoed for­mer FDA com­mis­sion­er Scott Got­tlieb’s com­ments from last week in the phar­ma’s Q4 earn­ings call this morn­ing con­cern­ing its amy­loid-tar­get­ed Alzheimer’s drug do­nanemab — and how the de­ci­sion by CMS to re­strict re­im­burse­ments on all an­ti-amy­loid mAbs could put this field of re­search in jeop­ardy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER